15-PGDH Inhibitor Compounds for Multi-Disease Substrate Control

The patent applies parameter changes by developing novel chemical compounds with specific molecular structures (formula I, II, or III) that have optimized parameters for binding to 15-PGDH enzyme. These compounds feature specific substituent groups (R1-R6, L, G, o) that can be varied to tune the inhibitory activity, selectivity, and pharmacokinetic properties, thereby improving therapeutic effectiveness across multiple disease types.

The patent achieves universality by creating a multi-functional compound class that can address diverse pathological conditions through a common mechanism of 15-PGDH inhibition. The compounds are designed to regulate 15-PGDH activity across different tissue types and disease states (fibrosis, inflammation, cardiovascular diseases, autoimmune diseases, neurological disorders), providing a universal therapeutic approach for multiple indications.

The patent applies preliminary anti-action by using the compounds to prevent the inactivation of 15-PGDH substrates before pathological processes can progress. By inhibiting 15-PGDH enzyme activity, the compounds preserve substrate levels (such as prostaglandins and inflammation-resolving lipid mediators) that would otherwise be degraded, thereby preventing disease progression in conditions like fibrosis, inflammation, and cardiovascular diseases.

The patent converts the harmful effect of 15-PGDH-mediated substrate inactivation into a beneficial therapeutic outcome. By targeting and inhibiting the enzyme responsible for substrate degradation, the compounds transform the pathological loss of protective substrates into increased substrate availability, which exerts therapeutic effects across multiple disease models including pulmonary fibrosis, inflammatory bowel disease, and cardiovascular disorders.